#ASCO16 news about #melanoma #skincancer

Online now: CheckMate064-nivolumab then ipilimumab more beneficial, more tox vs reverse order in #melanoma https://t.co/dpiSm9c5uq #ASCO16

— The Lancet Oncology (@TheLancetOncol) June 4, 2016

#ASCO16 news about #melanoma #skincancer

#keytruda shows some early benefit in some but not all sarcoma patients –Dr D'Angelo #asco16 pic.twitter.com/dtbGrmzhJj

— Eric D Whitman, MD (@Melanoma_doctor) June 5, 2016

#ASCO16 news about #melanoma #skincancer

#ASCO16 Join Arie Crown Th. 2.15PM Pr Robert @GustaveRoussy KEYNOTE-001 Results: 3-y overall survival for pts w/pembro in advanced #melanoma

— GustaveRoussy (@GustaveRoussy) June 6, 2016

#ASCO16 news about #melanoma #skincancer

Predictive biomarkers for #checkpoint inhibitors, #immunotherapy, in #melanoma and #crc. https://t.co/Ewhdr0cFvU #ASCO16 @VUMChealth

— AJMC-Oncology (@EBOncology) June 6, 2016

#ASCO16 news about #melanoma #skincancer

In which patients with #melanoma should sentinel lymph node biopsy be pursued? https://t.co/WeFysq4uIg #ASCO16

— ASCO (@ASCO) June 4, 2016

#ASCO16 news about metastatic #melanoma #skincancer

The Evolving Treatment Landscape of Metastatic #Melanoma: From Ipilimumab to New Checkpoint Inhibitors https://t.co/yypM2sZmUP #ASCO16

— ASCO (@ASCO) June 4, 2016

#ASCO16 news about metastatic #melanoma #skincancer

Examining the role of combination #immunotherapy treatment for patients w/ metastatic melanoma https://t.co/K4HkHD8tEj #ASCO16

— ASCO (@ASCO) June 4, 2016

About #asco16 Educational Book. Among others #melanoma #skincancer

Over 250 oncologists and researchers contributed to the #ASCO16 Educational Book. Have you read it yet? https://t.co/aKanDBqqsc

— ASCO (@ASCO) June 5, 2016